文献速递瓣膜病与结构性心脏病

经导管主动脉瓣置换术结局趋势:STS/ACC TVT注册研究解读

Trends in Transcatheter Aortic Valve Replacement Outcomes: Insights From the STS/ACC TVT Registry.
PubMed 文献 · JAMA Cardiol · 2024-01-01

未发现可解释该趋势的站点、患者或流程相关因素。

要点

  • 未调整30天死亡率从2019年Q1的2.4%到2022年Q1末的2.2%,无显著变化。
  • 风险调整后30天死亡率每年轻度上升,调整后OR为1.09(95%CI 1.05-1.13)。
  • 未发现站点、患者或流程相关因素能解释风险调整后死亡率上升趋势。

核心结论

  • 风险调整后30天死亡率从2019年1月至2022年3月轻度上升,但未调整死亡率无显著变化,需持续监测。

主要发现

  • 调整患者特征后OR为1.05/年(95%CI 1.02-1.08),进一步调整手术特征后OR为1.09/年(95%CI 1.05-1.13)。
  • 排除2019年或之后进入注册的站点、低容量站点、低风险患者、二叶式主动脉瓣患者、院内死亡或发生主要血管并发症的患者后,调整OR均无实质性变化。

临床怎么用

  • TAVR术后风险调整死亡率轻度上升趋势需持续监测,但未发现可解释因素,临床应关注患者选择和手术质量。

局限性

  • 观察性研究,不能排除未测量混杂因素;未发现站点、患者或流程相关因素能解释风险调整后死亡率上升。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although transcatheter aortic valve replacement (TAVR) outcomes in the US have improved substantially since 2011, it is unknown whether these trends have continued since 2019. OBJECTIVE: To examine changes in risk-adjusted TAVR outcomes from 2019 to 2022 and to examine any noteworthy trends over time. DESIGN, SETTING, AND PARTICIPANTS: This cohort study examined data from patients with severe aortic stenosis treated with TAVR at 786 US hospitals between January 1, 2019, and March 31, 2022, included in the Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapies (TVT) Registry. EXPOSURE: Patients who underwent TAVR. MAIN OUTCOMES AND MEASURES: The primary outcome was 30-day mortality, and the secondary outcomes were in-hospital mortality and 30-day composite adverse events. To understand factors explaining these trends, a series of logistic regression models was constructed for each outcome, with time as the primary explanatory variable. After adjusting for changing patent characteristics and procedural factors, a series of exploratory analyses was performed to examine the extent to which these findings could be explained by several plausible hypotheses. RESULTS: This study's analytic cohort included a total of 210 495 patients. Median (IQR) patient age was 79 (73-85) years, and 91 313 patients (43.4%) were female. Median (IQR) STS predicted risk of mortality (PROM) was 3.3% (2.0%-5.3%). There were no significant changes in unadjusted 30-day mortality from quarter 1 of 2019 (2.4%) to the end of quarter 1 of 2022 (2.2%) (P for trend = .10), with an unadjusted odds ratio (OR) for time of 0.98 per year (95% CI, 0.94-1.01). After adjusting for patient characteristics, the OR increased to 1.05 per year (95% CI, 1.02-1.08), which increased further after adjusting for procedural characteristics to 1.09 per year (95% CI, 1.05-1.13). In exploratory analyses, there were no meaningful changes in the adjusted odds of death after excluding sites that entered the STS/ACC TVT Registry in 2019 or later (OR, 1.09; 95% CI, 1.05-1.13), low-volume sites (OR, 1.09; 95% CI, 1.06-1.13), low-risk patients (OR, 1.11; 95% CI, 1.07-1.15), patients with a bicuspid aortic valve (OR, 1.09; 95% CI, 1.05-1.13), in-hospital deaths (OR, 1.08; 95% CI, 1.03-1.14), or patients who experienced a major vascular complication (OR, 1.09; 95% CI, 1.05-1.12). CONCLUSIONS AND RELEVANCE: In this observational cohort study performing a national analysis of outcomes after TAVR, it was found that risk-adjusted 30-day mortality increased modestly from January 2019 to March 2022. However, no site-level, patient-related, or process-related factors were identified that could explain these findings. Although the absolute increase in risk-adjusted mortality during the study period was relatively small, these findings warrant continued surveillance.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Arnold SV, Manandhar P, Vemulapalli S, et al. Trends in Transcatheter Aortic Valve Replacement Outcomes: Insights From the STS/ACC TVT Registry. JAMA Cardiol. 2024. PMID: 39412793. doi:10.1001/jamacardio.2024.3453

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。